STOCK TITAN
  1. Home
  2. News
  3. CBAY

Cymabay Therapeutics Inc - CBAY STOCK NEWS

Welcome to our dedicated news page for Cymabay Therapeutics (Ticker: CBAY), a resource for investors and traders seeking the latest updates and insights on Cymabay Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cymabay Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cymabay Therapeutics's position in the market.

News
Gilead Sciences Announces Completion of Acquisition of CymaBay
Rhea-AI Summary
Gilead Sciences, Inc. completes the acquisition of CymaBay Therapeutics, Inc. for $4.3 billion, enhancing its liver disease treatment portfolio with seladelpar for primary biliary cholangitis. The transaction reduces Gilead's 2024 EPS by approximately $3.10 - $3.20 due to acquisition costs and operating expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
acquisition
-
News
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
Rhea-AI Summary
CymaBay Therapeutics, Inc. announces the validation of the Marketing Authorization Application (MAA) for seladelpar, a potential treatment for primary biliary cholangitis (PBC) in Europe, with positive clinical data from Phase 3 studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
none
-
News
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
CymaBay Therapeutics, Inc. announces a pending acquisition by Gilead Sciences, Inc. for $4.3 billion, with seladelpar receiving FDA priority review. Financial results show $31.1 million collaboration revenue and $416.2 million cash on hand.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
earnings
News
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
Rhea-AI Summary
CymaBay Therapeutics, Inc. announces positive results of the RESPONSE Phase 3 trial for seladelpar in treating primary biliary cholangitis (PBC) published in The New England Journal of Medicine. Seladelpar showed significant improvements in liver biomarkers, reduction in pruritus, and normalization of ALP levels in patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
clinical trial
-
News
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
CymaBay Therapeutics, Inc. granted 99,000 stock options to three employees on February 16, 2024, with an exercise price of $32.18 per share. The options will vest over time based on continued employment, aiming to incentivize and retain key talent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
News
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Rhea-AI Summary
CymaBay Therapeutics, Inc. (CBAY) announced that the FDA accepted its NDA for seladelpar, a treatment for PBC, with a target PDUFA date of August 14. Seladelpar has shown significant improvements in PBC-related markers and pruritus in Phase 3 studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.38%
Tags
clinical trial
News
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Rhea-AI Summary
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to add seladelpar, a PPARδ agonist for the treatment of Primary Biliary Cholangitis (PBC), with FDA priority review and anticipated US approval in the third quarter of 2024. Seladelpar Phase 3 data showcases a best-in-disease profile for second-line PBC, expanding Gilead's liver disease portfolio and commitment to patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.38%
Tags
acquisition
-
News
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced its management team's participation in upcoming healthcare conferences, including the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, Raymond James & Associates’ 45th Annual Institutional Investors Conference, and Leerink Partners Global Biopharma Conference. The conferences aim to showcase the company's innovative therapies for liver and chronic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences
-
News
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) granted inducement awards to two employees on January 12, 2024. The Compensation Committee approved the grant of non-qualified stock options to purchase 52,000 shares of CymaBay common stock. The stock options have an exercise price of $23.76 per share and will vest over time based on the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
News
New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
Rhea-AI Summary
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 (IL-31) levels and its correlation with pruritus improvement in people with primary biliary cholangitis (PBC). The Phase 3 ENHANCE study showed statistically significant dose-dependent decreases in IL-31 with seladelpar compared to placebo. The findings were published in the open access journal Hepatology, marking a significant step in understanding the potential mediators of cholestatic itch and suggesting novel therapeutic approaches for PBC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
clinical trial
Stock CBAY logo
Cymabay Therapeutics Inc

Nasdaq:CBAY

CBAY Rankings

N/A Ranked by Market Cap
#14 Ranked by Stock Gains
N/A Ranked by Dividends

CBAY Stock Data

3.73B
96.64M
0.52%
103.13%
5.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About CBAY

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.